Answers are grounded in this paper and cite their sources.
Challenges isolating digitalis effects amid transient noncardiac precipitants; leaves open optimal titration methods in such HF.
CARDIAC failure is frequently precipitated by a noncardiac illness. Although digitalis is used to restore and maintain compensation, the self-limiting nature of the precipitating event or its response to specific therapy may make it difficult or impossible to determine the effects of digitalis. To give a so-called digitalizing dose at one time does not answer this problem because almost always no immediate effects are seen.1 , 2 Dissipation of symptoms and signs of cardiac failure requires a variable time, measurable in days, weeks or even months. One rightly hesitates to increase the so-called digitalizing dose for fear of producing prolonged toxicity or . . .
No takes yet. Share an insight, caveat, or question.
Soloff et al. (1956) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: